[Treatment of lipid disorders].
Lipid disorders play an essential role in the pathogenesis of atherosclerotic diseases. An integral part of the clinical evaluation is the estimation of the individual cardiovascular risk using risk scores and patient history. Due to the long established prognostic relevance, reduction of low-density lipoproteins (LDL) using statins remains beyond doubt the central intervention both in primary and secondary prevention of atherosclerotic diseases. Indispensible components of treatment in all patients with elevated triglyceride levels are lifestyle changes contributing to a reduction of accompanying risk factors, in particular physical activity and smoking cessation.
Klinik f. Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinik des Saarlandes, 66421, Homburg/Saar, Deutschland, florian.custodis@uks.eu.
F
F
Custodis
U
U
Laufs
D003131:Combined Modality Therapy / Q000379:methods; D005081:Exercise Therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006949:Hyperlipidemias / Q000175:diagnosis / Q000628:therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D040242:Risk Reduction Behavior; D016540:Smoking Cessation
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents